Everyone seems to be on one. Semaglutide, tirzepatide, the newer triple agonist everyone in the gym is whispering about. Somewhere along the way, we started treating them like a vitamin. Something you just take. I think that is a mistake.
Not because these drugs are bad. They are impressive. But "no big deal" does not match what they are actually doing inside your body. This is my attempt at the complete picture: the good, the rarely mentioned, and the part almost no one connects to you specifically, which is your genetics. This is my opinion and education, not medical advice. Talk to your doctor about your own situation.
01First, the promise is real
Let me be fair to these drugs, because they earn it. They drive real weight loss. They improve blood sugar. The benefits now reach into heart health, kidney health, and fatty liver. There are even early, interesting signals around inflammation and the gut.
For someone carrying serious metabolic disease, the math is clear. The benefits outweigh the costs, often dramatically. So this is not an anti-drug piece. Hold that thought, because the rest only makes sense if you believe me on this part.
02It reaches further than you think
Here is what gets lost in the before-and-after photos. These drugs do not just quiet your appetite. They touch systems most people never hear about.
Muscle. A large share of the weight you lose can be muscle, not fat. Up to 40 percent on some drugs. Less appetite means less protein, and your body starts borrowing from muscle.
Bone and nutrients. About one in five users develops a nutrient deficiency within a year. Vitamin D, iron, B12, calcium, protein. Bone density measurably drops too, and the loss tracks with how much weight comes off.
The reward system. This is the one I find most under-discussed. The same brain circuit that quiets food cravings can quiet everything else. Some people describe the world going a little gray. Food stops being exciting, but so do hobbies, music, plans. For most people the effect is mild and selective. For some, it is a real flatness that can linger for months.
The gut. Slowed digestion, gallbladder strain, and for some, stubborn nausea that does not fade.
None of this means the drug is dangerous. It means the drug is powerful. It reaches a lot. And reaching a lot cuts both ways.
03The people with the most to lose
Here is where I get most concerned. Almost all the research was done on people with obesity or diabetes. The person who just wants to drop 10 or 20 pounds for a wedding or a beach trip was never really studied. And for that person, the math quietly flips.
When you do not have much fat to lose, more of the loss comes from muscle and bone instead. You can end up lighter but weaker, with thinner bones, for a cosmetic goal. Telling detail: the bone loss appears greater in people who were not diabetic to begin with. The closer you are to the "just a few pounds" user, the more it seems to show up.
Then there is the round trip. Most people stop eventually. The weight that comes back tends to come back as fat, not the muscle you lost. So you can land at a worse body composition than where you started. Same number on the scale, less muscle, more fat. You kept all the costs. You lost most of the benefit.
04We do not have the years yet
This is the quiet truth under all of it. Semaglutide has only been in wide use for weight loss since about 2021. Tirzepatide is newer. Retatrutide is newer still, and not officially available yet.
So when someone asks what a decade of this does to muscle, bone, the reward system, or the gut, the honest answer is that nobody knows. People are not waiting for the long-term study. They are the long-term study. They just were not told that.
The strongest drug is not the right drug. The right one is the one that matches your biology.
05The twist: your DNA is already in the room
Now the part that, to me, is the most interesting and the most overlooked. How well these drugs work, and how badly they hit you, is partly written in your genes. A large 2026 genetics study landed on a few findings worth sitting with.
About 1 in 10 people barely respond. They lose less than 5 percent even at a full dose. A variant in the GLP1R gene, the receptor these drugs bind, predicts how much weight you actually lose. And a variant in the GIPR gene predicts nausea and vomiting, but only on the drugs that hit that receptor.
The part that stops me cold: the genetics for "loses the most weight" and the genetics for "feels the sickest" seem to overlap. The strongest responders may be the ones biologically set up to suffer most. Most people start these drugs completely blind to all of this.
06So who is suited to which one?
This is a framework, not a prescription. The science is early. But the logic is sound, and it reframes the whole decision: from "which drug is strongest" to "which drug is right for me." Those were never the same question.
Most studied, gentlest profile. A smart fit if you carry the favorable response variant, and especially if you are prone to nausea, since it does not touch the GIP receptor that drives a lot of the sickness.
Stronger appetite control and more weight loss. Best for someone who tolerates things well. A worse fit if your genetics point to more nausea (the GIPR variant) or a blunted response (the TCF7L2 variant).
Adds a fat-burning, energy-raising arm, which the body-composition crowd loves. Highest ceiling, least data, no genetic-matching research yet, and not officially on the market, so most people sourcing it are doing so through unofficial channels.
07Where this leaves us
These drugs can be a real tool. I am not here to take them away from anyone. But a tool this powerful deserves respect, not a shrug. It deserves the nutrition, the protein, the strength work, and the bloodwork underneath it. And ideally, it deserves a look at your own genetics before you start, not after.
The strongest version of this is not "should I take it." It is "what does my biology say about whether this is the right tool, which one, and at what cost." That is the question worth asking. And it is the one almost no one is.